Table 1 Correlation between IMPDH2 expression and clinical and pathological characters in NPC patients.

From: High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma

Variable All cases N = 226 (%) IMPDH2 protein P value
Low expression N = 103 (%) High expression N = 123 (%) χ2
Age(years)     0.054 0.817
≤44 116 (51.3) 52 (44.8) 64 (55.2)   
>44 110 (48.7) 51 (46.4) 59 (53.6)   
Mean ± SD(44.4 ± 11.4)
Gender     1.097 0.295
Female 52 (23.0) 27 (51.9) 25 (48.1)   
Male 174 (77.0) 76 (43.7) 98 (56.3)   
VCA-IgA     1.713 0.191
<1:80 32 (14.2) 18 (56.3) 14 (43.7)   
≥1:80 194 (85.8) 85 (43.8) 109 (56.2)   
EA-IgA     0.705 0.401
<1:10 64 (28.3) 32 (50.0) 32 (50.0)   
≥1:10 162 (71.7) 71 (43.8) 91 (56.2)   
T classification     5.188 0.023*
T1-2 85 (37.6) 47 (55.3) 38 (44.7)   
T3-4 141 (62.4) 56 (39.7) 85 (60.3)   
N classification     0.362 0.547
N0 55 (24.3) 27 (49.1) 28 (50.9)   
N1-3 171 (75.7) 76 (44.4) 95 (55.6)   
TNM stage     5.390 0.020*
I-II 64 (28.3) 37 (57.8) 27 (42.2)   
III-IV 162 (71.7) 66 (40.7) 96 (59.3)   
WHO type     <0.001 0.990
I + II 22 (9.7) 10 (45.5) 12 (54.5)   
III 204 (90.3) 93 (45.6) 111 (54.4)   
Distant metastasis     10.561 0.001*
Yes 61 (27.0) 17 (27.9) 44 (72.1)   
No 165 (73.0) 86 (52.1) 79 (47.9)   
Death     9.919 0.002*
Yes 50 (22.1) 13 (26.0) 37 (74.0)   
No 176 (77.9) 90 (51.1) 86 (48.9)   
  1. VCA-IgA: viral capsid antigen immunoglobulin A; EA-IgA: early antigen immunoglobulin A; WHO: World Health Organization; P-values*were calculated using the chi-square test or Fisher’s exact test.